Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Core Insights - Aclarion has secured its first payer coverage for Nociscan from AXA, marking a significant milestone for the company in the UK healthcare market [1][2] - The approval by AXA, which holds approximately 30% of the private medical insurance market in the UK, is expected to drive volume and revenue for Aclarion [1][2] - Nociscan is being adopted by The London Clinic as a decision support tool for diagnosing and treating chronic low back pain, expanding access for insured patients [3] Company Overview - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in treatment [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [4] - The company aims to optimize clinical treatments by leveraging biomarkers and augmented intelligence algorithms [4] Market Context - In the UK, self-pay and private medical insurance account for nearly 70% of private hospital revenues, indicating a growing market for private medical insurance [2] - AXA is one of the four leading private medical insurers in the UK, with an estimated 3 million insured customers [2]